StockData

Mosaic ImmunoEngineering Inc. (CPMV) shareholders

CPMVOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 3/30
$0.33+0.00 (0.00%)

Close on Oct 19, 2026Market cap $2.41MP/E –Yield –

Ownership

Institutional holdings as of Sep 30, 2025, from 13F filings

Held by institutions
0.0%
0M of 7M shares
Institutional holders
1
0 new, 0 sold out
Net institutional buying
0M
In Q3 2025
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Top institutional holders

13F holdings as of Sep 30, 2025

HolderShares% of CPMVValueChange% of portfolio
West Oak Capital, LLC10.00%$0–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q3 202510M0.0%0 / 00 / 00M0M
Q2 202510M0.0%0 / 00 / 00M0M
Q1 202510M0.0%0 / 00 / 00M0M
Q4 202410M0.0%0 / 00 / 00M0M
Q3 202410M0.0%0 / 00 / 00M0M
Q2 202410M0.0%0 / 00 / 00M0M
Q1 202410M0.0%0 / 00 / 00M0M
Q4 202310M0.0%0 / 00 / 00M0M
Q3 202310M0.0%0 / 00 / 00M0M
Q2 202310M0.0%0 / 00 / 00M0M
Q1 202310M0.0%0 / 00 / 00M0M
Q4 202210M0.0%0 / 00 / 00M0M

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Robert L. Garnick
Director
Jan 29, 2021Conversion+356,794––356,794
Steven W. King
President and CEO, Director, 10% owner
Jan 29, 2021Conversion+1,641,252––1,641,252
Paul J. Lytle
EVP, Chief Financial Officer, Director, 10% owner
Jan 29, 2021Conversion+1,641,252––1,641,252
Nicole Franziska Steinmetz
Acting CSO, Director, 10% owner
Jan 29, 2021Conversion+570,870––570,870
Nicole Franziska Steinmetz
Acting CSO, Director, 10% owner
Jan 29, 2021Conversion+1,641,252––1,641,252
Clifford L. Flowers
CFO and Interim CEO
Apr 17, 2013Option exercise+75,000$0.10$7.50K75,000
Gloria Felcyn
Director
Apr 30, 2012Award+48,200$0.10$4.82K951,690
Gloria Felcyn
Director
Apr 27, 2012Award+4,500$0.10$450903,490
Gloria Felcyn
Director
Apr 26, 2012Award+89,290$0.10$8.93K898,990
Helmut Falk Jr
Director
Dec 9, 2009Option exercise+100,000$0.07$7.00K2,622,731
Helmut Falk Jr
Director
Oct 27, 2009Sale−25,000$0.30$7.50K2,522,731
Paul R. Bibeau
VP, Business Development
Apr 15, 2009Buy+100,000$0.10$10.00K400,000
Paul R. Bibeau
VP, Business Development
Jan 30, 2009Buy+98,000$0.12$11.76K298,000
Paul R. Bibeau
VP, Business Development
Jan 30, 2009Buy+2,000$0.11$220300,000
Carlton M. Johnson
Director
Nov 26, 2008Buy+46,800$0.12$5.62K431,800
Carlton M. Johnson
Director
Nov 26, 2008Buy+30,000$0.11$3.30K461,800
Carlton M. Johnson
Director
Nov 26, 2008Buy+63,200$0.11$6.95K525,000
Carlton M. Johnson
Director
Nov 25, 2008Buy+10,000$0.11$1.10K385,000
Helmut Falk Jr
Director
Nov 21, 2008Buy+100,000$0.11$11.00K200,000
Frederick C. Goerner
Chief Executive Officer
Nov 21, 2008Buy+80,000$0.12$9.60K400,000
Frederick C. Goerner
Chief Executive Officer
Nov 21, 2008Buy+20,000$0.11$2.20K320,000
Paul R. Bibeau
VP, Business Development
Nov 21, 2008Buy+62,780$0.11$6.91K122,780
Paul R. Bibeau
VP, Business Development
Nov 21, 2008Buy+10,000$0.11$1.10K60,000
Paul R. Bibeau
VP, Business Development
Nov 21, 2008Buy+15,500$0.11$1.71K138,280
Paul R. Bibeau
VP, Business Development
Nov 21, 2008Buy+61,720$0.12$7.41K200,000
Frederick C. Goerner
Chief Executive Officer
Nov 20, 2008Buy+189,000$0.12$22.68K300,000
Frederick C. Goerner
Chief Executive Officer
Nov 20, 2008Buy+111,000$0.11$12.21K111,111
Harry L. Tredennick
Director
Nov 20, 2008Buy+115,959$0.11$12.76K115,959
Harry L. Tredennick
Director
Nov 20, 2008Buy+64,041$0.11$7.04K180,000
Carlton M. Johnson
Director
Nov 20, 2008Buy+100,000$0.11$11.00K375,000
Gloria Felcyn
Director
Nov 20, 2008Buy+36,520$0.11$4.02K658,870
Gloria Felcyn
Director
Nov 20, 2008Buy+163,480$0.12$19.62K822,350
Gloria Felcyn
Director
Nov 20, 2008Buy+5,000$0.11$550827,350
Gloria Felcyn
Director
Nov 20, 2008Buy+75,000$0.11$8.25K622,350
Helmut Falk Jr
Director
Oct 21, 2008Option exercise+100,000$0.05$5.00K2,543,231
Helmut Falk Jr
Director
Jun 30, 2008Buy+50,000$0.19$9.50K2,603,231
Helmut Falk Jr
Director
Jun 30, 2008Buy+50,000$0.20$10.00K2,553,231
Paul R. Bibeau
VP, Business Development
Apr 24, 2008Buy+50,000$0.37$18.50K50,000
Frederick C. Goerner
Chief Executive Officer
Apr 15, 2008Buy+190,000$0.33$62.70K290,000
Frederick C. Goerner
Chief Executive Officer
Apr 15, 2008Buy+10,000$0.32$3.20K300,000
Gloria Felcyn
Director
Apr 15, 2008Buy+10,000$0.31$3.10K499,700
Gloria Felcyn
Director
Apr 15, 2008Buy+5,000$0.32$1.60K504,700
Gloria Felcyn
Director
Apr 15, 2008Buy+25,000$0.32$8.00K529,700
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+5,000$0.39$1.95K65,000
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+7,500$0.39$2.93K35,000
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+10,000$0.39$3.90K45,000
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+5,000$0.38$1.90K22,500
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+7,500$0.38$2.85K17,500
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+10,000$0.38$3.80K10,000
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+2,500$0.39$975100,000
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+25,000$0.39$9.75K97,500
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+7,500$0.39$2.93K72,500
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+5,000$0.38$1.90K27,500
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+7,500$0.39$2.93K60,000
Frederick C. Goerner
Chief Executive Officer
Mar 4, 2008Buy+7,500$0.39$2.93K52,500
Gloria Felcyn
Director
Sep 14, 2007Option exercise+100,000$0.10$10.00K489,700
David Pohl
Director
Aug 28, 2007Tax withholding−173,404$0.47$81.50K1,882,846
David Pohl
Director
Aug 28, 2007Option exercise+500,000$0.16$80.00K2,056,250
Helmut Falk Jr
Director
Aug 7, 2007Option exercise+25,000$0.07$1.75K2,503,231
David Pohl
Director
Aug 6, 2007Option exercise+1,000,000$0.17$170.00K1,900,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+330.6%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Mosaic ImmunoEngineering's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?